Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Dornase alfa (Primary)
- Indications Respiratory tract infections
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 Oct 2017 Status changed from recruiting to completed.
- 11 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.